
Orphan designated precision drug approved in US for NSCLC
The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib with… Read More















